Led by Frank Sciurba, MD, the OBERON and TITANIA studies highlight the potential of targeting IL-33 to address a major unmet need in COPD care.
New COPD Biologic Meets Endpoints in Landmark Phase III Trials
Led by Frank Sciurba, MD, the OBERON and TITANIA studies highlight the potential of targeting IL-33 to address a major unmet need in COPD care.